207 related articles for article (PubMed ID: 21571964)
1. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases.
Coleman JF; Theil KS; Tubbs RR; Cook JR
Am J Clin Pathol; 2011 Jun; 135(6):915-20. PubMed ID: 21571964
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
Sun Y; Cook JR
Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.
McDevitt MA; Condon M; Stamberg J; Karp JE; McDiarmid M
Mutat Res; 2007 Apr; 629(1):24-31. PubMed ID: 17276720
[TBL] [Abstract][Full Text] [Related]
4. [Study on the role of fluorescence in situ hybridization in cytogenetic evaluation of myelodysplastic syndrome].
Qu SQ; Xu ZF; Li CW; Liu XP; Qin TJ; Zhang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):839-42. PubMed ID: 23384907
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
[TBL] [Abstract][Full Text] [Related]
7. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
[TBL] [Abstract][Full Text] [Related]
8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
9. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
Gao DG; Li BT; Zhou LN; Chen H; Zhang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
[TBL] [Abstract][Full Text] [Related]
10. Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia.
Donahue AC; Abdool AK; Gaur R; Wohlgemuth JG; Yeh CH
Leuk Res; 2011 Nov; 35(11):1477-83. PubMed ID: 21764131
[TBL] [Abstract][Full Text] [Related]
11. Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia.
Royer-Pokora B; Trost D; Müller N; Hildebrandt B; Germing U; Beier M
Cancer Genet Cytogenet; 2006 May; 167(1):66-9. PubMed ID: 16682289
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia.
Fröhling S; Kayser S; Mayer C; Miller S; Wieland C; Skelin S; Schlenk RF; Döhner H; Döhner K;
Haematologica; 2005 Feb; 90(2):194-9. PubMed ID: 15710571
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
14. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases.
Sashida G; Ohyashiki JH; Nakajima A; Sumi M; Kawakubo K; Tauchi T; Ohyashiki K
Clin Cancer Res; 2003 Apr; 9(4):1489-96. PubMed ID: 12684424
[TBL] [Abstract][Full Text] [Related]
15. Submicroscopic deletions in 5q- associated malignancies.
Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
[TBL] [Abstract][Full Text] [Related]
16. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
17. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
Yilmaz Z; Sahin FI; Kizilkilic E; Karakus S; Boga C; Ozdogu H
Clin Exp Med; 2005 Jul; 5(2):55-9. PubMed ID: 16096854
[TBL] [Abstract][Full Text] [Related]
18. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
Cherry AM; Slovak ML; Campbell LJ; Chun K; Eclache V; Haase D; Haferlach C; Hildebrandt B; Iqbal AM; Jhanwar SC; Ohyashiki K; Sole F; Vandenberghe P; VanDyke DL; Zhang Y; Dewald GW
Leuk Res; 2012 Jul; 36(7):832-40. PubMed ID: 22537394
[TBL] [Abstract][Full Text] [Related]
19. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
Kokate P; Dalvi R; Koppaka N; Mandava S
Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
[TBL] [Abstract][Full Text] [Related]
20. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?
Costa D; Valera S; Carrió A; Arias A; Muñoz C; Rozman M; Belkaid M; Coutinho R; Nomdedeu B; Campo E
Leuk Res; 2010 Nov; 34(11):1437-41. PubMed ID: 20226525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
